経口メサラジンのグローバル市場2023年:錠剤、カプセル、顆粒

【英語タイトル】Global Oral Mesalazine Market Research Report 2023

QYResearchが出版した調査資料(QYR23MA8837)・商品コード:QYR23MA8837
・発行会社(調査会社):QYResearch
・発行日:2023年3月
・ページ数:87
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後2-3営業日)
・調査対象地域:グローバル
・産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,900 ⇒換算¥377,000見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD4,350 ⇒換算¥565,500見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD5,800 ⇒換算¥754,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査レポートは世界の経口メサラジン市場について調査・分析し、世界の経口メサラジン市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析(錠剤、カプセル、顆粒)、用途別セグメント分析(潰瘍性大腸炎、クローン病、炎症性腸疾患、その他)、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、AbbVie、Shire、Salix Pharmaceuticals、Ferring Global、Teva Pharmaceutical Industries、Morningside Healthcare、Dr. Falk Pharma UK、Nogra Pharma Limited、Tillotts Pharmaなどが含まれています。世界の経口メサラジン市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX%です。COVID-19とロシア・ウクライナ戦争の影響は、経口メサラジン市場規模を推定する際に考慮しました。

・経口メサラジン市場の概要
- 経口メサラジンのタイプ別セグメント
- 世界の経口メサラジン市場規模:タイプ別分析(錠剤、カプセル、顆粒)
- 経口メサラジンの用途別セグメント
- 世界の経口メサラジン市場規模:用途別分析(潰瘍性大腸炎、クローン病、炎症性腸疾患、その他)
- 世界の経口メサラジン市場規模予測(2018年-2029年)

・経口メサラジン市場の成長トレンド
- 経口メサラジンの地域別市場規模(2018年-2029年)
- 経口メサラジン市場ダイナミクス
- 経口メサラジンの業界動向
- 経口メサラジン市場の成長ドライバ、課題、阻害要因

・主要企業別競争状況
- 企業別市場シェア
- 世界の主要企業、業界ランキング分析
- 市場への参入、M&A動向

・タイプ別セグメント:錠剤、カプセル、顆粒
- 世界の経口メサラジンのタイプ別市場規模(2018年-2023年)
- 世界の経口メサラジンのタイプ別市場規模(2024年-2029年)

・用途別セグメント:潰瘍性大腸炎、クローン病、炎症性腸疾患、その他
- 世界の経口メサラジンの用途別市場規模(2018年-2023年)
- 世界の経口メサラジンの用途別市場規模(2024年-2029年)

・経口メサラジンの地域別市場規模
- 北米の経口メサラジン市場規模(2018年-2029年)
- アメリカの経口メサラジン市場規模(2018年-2029年)
- ヨーロッパの経口メサラジン市場規模(2018年-2029年)
- アジア太平洋の経口メサラジン市場規模(2018年-2029年)
- 中国の経口メサラジン市場規模(2018年-2029年)
- 日本の経口メサラジン市場規模(2018年-2029年)
- 韓国の経口メサラジン市場規模(2018年-2029年)
- インドの経口メサラジン市場規模(2018年-2029年)
- オーストラリアの経口メサラジン市場規模(2018年-2029年)
- 中南米の経口メサラジン市場規模(2018年-2029年)
- 中東・アフリカの経口メサラジン市場規模(2018年-2029年)

・主要企業のプロファイル:企業情報、事業概要、売上、動向
AbbVie、Shire、Salix Pharmaceuticals、Ferring Global、Teva Pharmaceutical Industries、Morningside Healthcare、Dr. Falk Pharma UK、Nogra Pharma Limited、Tillotts Pharma

・アナリストの観点/結論

・調査方法とデータソース
❖ レポートの概要 ❖

Highlights
The global Oral Mesalazine market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Oral Mesalazine is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Oral Mesalazine is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Oral Mesalazine in Ulcerative Colitis is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Oral Mesalazine include AbbVie, Shire, Salix Pharmaceuticals, Ferring Global, Teva Pharmaceutical Industries, Morningside Healthcare, Dr. Falk Pharma UK, Nogra Pharma Limited and Tillotts Pharma, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Oral Mesalazine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oral Mesalazine.
The Oral Mesalazine market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Oral Mesalazine market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oral Mesalazine companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
AbbVie
Shire
Salix Pharmaceuticals
Ferring Global
Teva Pharmaceutical Industries
Morningside Healthcare
Dr. Falk Pharma UK
Nogra Pharma Limited
Tillotts Pharma
Segment by Type
Tablets
Capsules
Granule
Segment by Application
Ulcerative Colitis
Crohn’s Disease
Inflammatory Bowel Disease
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oral Mesalazine companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oral Mesalazine Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Tablets
1.2.3 Capsules
1.2.4 Granule
1.3 Market by Application
1.3.1 Global Oral Mesalazine Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Ulcerative Colitis
1.3.3 Crohn’s Disease
1.3.4 Inflammatory Bowel Disease
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oral Mesalazine Market Perspective (2018-2029)
2.2 Oral Mesalazine Growth Trends by Region
2.2.1 Global Oral Mesalazine Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Oral Mesalazine Historic Market Size by Region (2018-2023)
2.2.3 Oral Mesalazine Forecasted Market Size by Region (2024-2029)
2.3 Oral Mesalazine Market Dynamics
2.3.1 Oral Mesalazine Industry Trends
2.3.2 Oral Mesalazine Market Drivers
2.3.3 Oral Mesalazine Market Challenges
2.3.4 Oral Mesalazine Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oral Mesalazine Players by Revenue
3.1.1 Global Top Oral Mesalazine Players by Revenue (2018-2023)
3.1.2 Global Oral Mesalazine Revenue Market Share by Players (2018-2023)
3.2 Global Oral Mesalazine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Oral Mesalazine Revenue
3.4 Global Oral Mesalazine Market Concentration Ratio
3.4.1 Global Oral Mesalazine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oral Mesalazine Revenue in 2022
3.5 Oral Mesalazine Key Players Head office and Area Served
3.6 Key Players Oral Mesalazine Product Solution and Service
3.7 Date of Enter into Oral Mesalazine Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Oral Mesalazine Breakdown Data by Type
4.1 Global Oral Mesalazine Historic Market Size by Type (2018-2023)
4.2 Global Oral Mesalazine Forecasted Market Size by Type (2024-2029)
5 Oral Mesalazine Breakdown Data by Application
5.1 Global Oral Mesalazine Historic Market Size by Application (2018-2023)
5.2 Global Oral Mesalazine Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Oral Mesalazine Market Size (2018-2029)
6.2 North America Oral Mesalazine Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Oral Mesalazine Market Size by Country (2018-2023)
6.4 North America Oral Mesalazine Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Oral Mesalazine Market Size (2018-2029)
7.2 Europe Oral Mesalazine Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Oral Mesalazine Market Size by Country (2018-2023)
7.4 Europe Oral Mesalazine Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oral Mesalazine Market Size (2018-2029)
8.2 Asia-Pacific Oral Mesalazine Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Oral Mesalazine Market Size by Region (2018-2023)
8.4 Asia-Pacific Oral Mesalazine Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Oral Mesalazine Market Size (2018-2029)
9.2 Latin America Oral Mesalazine Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Oral Mesalazine Market Size by Country (2018-2023)
9.4 Latin America Oral Mesalazine Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oral Mesalazine Market Size (2018-2029)
10.2 Middle East & Africa Oral Mesalazine Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Oral Mesalazine Market Size by Country (2018-2023)
10.4 Middle East & Africa Oral Mesalazine Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Detail
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Oral Mesalazine Introduction
11.1.4 AbbVie Revenue in Oral Mesalazine Business (2018-2023)
11.1.5 AbbVie Recent Development
11.2 Shire
11.2.1 Shire Company Detail
11.2.2 Shire Business Overview
11.2.3 Shire Oral Mesalazine Introduction
11.2.4 Shire Revenue in Oral Mesalazine Business (2018-2023)
11.2.5 Shire Recent Development
11.3 Salix Pharmaceuticals
11.3.1 Salix Pharmaceuticals Company Detail
11.3.2 Salix Pharmaceuticals Business Overview
11.3.3 Salix Pharmaceuticals Oral Mesalazine Introduction
11.3.4 Salix Pharmaceuticals Revenue in Oral Mesalazine Business (2018-2023)
11.3.5 Salix Pharmaceuticals Recent Development
11.4 Ferring Global
11.4.1 Ferring Global Company Detail
11.4.2 Ferring Global Business Overview
11.4.3 Ferring Global Oral Mesalazine Introduction
11.4.4 Ferring Global Revenue in Oral Mesalazine Business (2018-2023)
11.4.5 Ferring Global Recent Development
11.5 Teva Pharmaceutical Industries
11.5.1 Teva Pharmaceutical Industries Company Detail
11.5.2 Teva Pharmaceutical Industries Business Overview
11.5.3 Teva Pharmaceutical Industries Oral Mesalazine Introduction
11.5.4 Teva Pharmaceutical Industries Revenue in Oral Mesalazine Business (2018-2023)
11.5.5 Teva Pharmaceutical Industries Recent Development
11.6 Morningside Healthcare
11.6.1 Morningside Healthcare Company Detail
11.6.2 Morningside Healthcare Business Overview
11.6.3 Morningside Healthcare Oral Mesalazine Introduction
11.6.4 Morningside Healthcare Revenue in Oral Mesalazine Business (2018-2023)
11.6.5 Morningside Healthcare Recent Development
11.7 Dr. Falk Pharma UK
11.7.1 Dr. Falk Pharma UK Company Detail
11.7.2 Dr. Falk Pharma UK Business Overview
11.7.3 Dr. Falk Pharma UK Oral Mesalazine Introduction
11.7.4 Dr. Falk Pharma UK Revenue in Oral Mesalazine Business (2018-2023)
11.7.5 Dr. Falk Pharma UK Recent Development
11.8 Nogra Pharma Limited
11.8.1 Nogra Pharma Limited Company Detail
11.8.2 Nogra Pharma Limited Business Overview
11.8.3 Nogra Pharma Limited Oral Mesalazine Introduction
11.8.4 Nogra Pharma Limited Revenue in Oral Mesalazine Business (2018-2023)
11.8.5 Nogra Pharma Limited Recent Development
11.9 Tillotts Pharma
11.9.1 Tillotts Pharma Company Detail
11.9.2 Tillotts Pharma Business Overview
11.9.3 Tillotts Pharma Oral Mesalazine Introduction
11.9.4 Tillotts Pharma Revenue in Oral Mesalazine Business (2018-2023)
11.9.5 Tillotts Pharma Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details



★調査レポート[経口メサラジンのグローバル市場2023年:錠剤、カプセル、顆粒] (コード:QYR23MA8837)販売に関する免責事項を必ずご確認ください。
★調査レポート[経口メサラジンのグローバル市場2023年:錠剤、カプセル、顆粒]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆